206872-01-7Relevant articles and documents
THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES
-
Paragraph 0090-0091; 0130-0131, (2021/05/06)
A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]
Synthesis of substituted 2-heteroarylbenzazol-5-ol derivatives as potential ligands for estrogen receptors
Rezazadeh, Sina,Navidpour, Latifeh,Shafiee, Abbas
, p. 6076 - 6082 (2013/07/19)
Exposure to estrogen is associated with increased risk of breast and other types of human cancer. One therapeutic goal would be the creation of new molecules that would retain hormonal potency while incorporating features to retard or prevent quinone toxicity. Hence, new structures closely related to ERB-041, a known ERβ selective agonist, were synthesized whereas the phenol ring is substituted with non-quinone forming rings such as pyrazole, 2-pyrimidine-2(1H)-one or pyridine-2(1H)-one. 2-Methyl-5-methoxy-1,3- benzoxazoles (or 1,3-benzothiazole) are key intermediates for the production of the pyrazole and pyrimidine-2(1H)-one analogs. The required 1,3-benzoxazoles were synthesized starting from reduction of 2-nitro-4-methoxyphenols, followed by condensation with trimethyl orthoacetate. Then, the diiminium perchlorate intermediates were prepared from the latter compounds by Vilsmeier-Haack reaction. The reaction of the resulting intermediates with hydrazine hydrate and guanidium chloride afforded the title pyrazole and pyrimidine-2(1H)-ones, respectively. The pyridine analogs were synthesized starting from the reaction of 2-amino-4-methoxyphenols with 6-bromopyridine-3-carboxaldehyde followed by oxidation with DDQ to afford bromopyridines. These compounds were next treated with benzyl alcohol in the presence of potassium tert-butoxide to afford 2-benzyloxypyridine, which in subsequent dealkylation with boron tribromide produced the title pyridine-2-(1H)-ones.
Aryl nitro reduction with iron powder or stannous chloride under ultrasonic irradiation
Gamble, Allan B.,Garner, James,Gordon, Christopher P.,O'Conner, Sean M. J.,Keller, Paul A.
, p. 2777 - 2786 (2008/02/12)
The selective reduction of aryl nitro compounds in the presence of sensitive functionalities, including halide, carbonyl, nitrile, and ester substituents, under ultrasonic irradiation at 35 kHz is reported in yields of 39-98%. Iron powder proved superior to stannous chloride with high tolerance of sensitive functional groups and high yields of the desired aryl amines in relatively short reaction times. Simple experimental procedure and purification also make the iron reduction of aryl nitro compounds advantageous over other methods of reduction. Copyright Taylor & Francis Group, LLC.
